Expectations for both companies are really high. Morningstar estimates the GLP-1 drug market will be worth $200bn by 2031, and analysts expect Eli Lilly and Novo Nordisk to take the lion’s share of it ...

Questor is The Telegraph’s stockpicking column, helping you decode the markets and offering insights on where to invest for ...

The 2024 increase is the same as last year.The foundation’s annual survey of employer health benefits also found that only 18 ...

Good evening. As Hurricane Milton barrels toward the west coast of Florida ahead of an expected landfall tonight, the ...

A recent research published in the Food Bioscience journal highlighted an critical connection between Type 2 taste receptors ...

Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiencyLONDON and NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Holdings ...

Some of the most valuable health advancements in 2024 related to weight loss and metabolic health. New findings about ...

A large study of veterans with type 2 diabetes finds better short-term kidney outcomes with use of SGLT2 inhibitors vs GLP-1 receptor agonists.

American adults prefer dietary change as a weight loss method, over injectable weight loss drugs such as Ozempic, a survey says.

While shares have posted break-even returns so far in 2024, Pfizer stock has cratered by more than 30% over the ...

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / October 9, ...